Navigation Links
Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
Date:4/22/2010

NEW YORK, LONDON and HAMILTON, Bermuda, April 22 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced the initiation of a Phase I/II pediatric dose tolerance trial to test their investigational new drug XERECEPT® in pediatric patients suffering from primary, recurrent or metastatic brain tumors.

Celtic Pharma's objective for this trial is to rapidly demonstrate the tolerability to increasing doses of XERECEPT® in pediatric patients.  Upon identification of the maximum tolerated dose, the study will continue to investigate the clinical benefits of XERECEPT® in this population, particularly with regard to reduction of dexamethasone dosing requirements and concomitant clinical benefit to the patients.  Dr. Stewart Goldman, medical director of the Neuro-Oncology unit at Northwestern University's Feinberg School of Medicine and the study's Principal Investigator commented, "I am excited to be working on this very important trial.  The effects of dexamethasone dosing on these children who have brain tumors is heart wrenching and I look forward to working with Celtic Pharma in the testing of XERECEPT® in these patients."

Stephen Evans-Freke, co-Managing General Partner of Celtic Pharma further commented, "The current standards of care and prognosis for pediatric patients with brain tumors is very poor and we believe that XERECEPT® may provide a welcome and needed treatment for these children, in whom the effects of high-dose steroids are so devastating.  We have been in close contact with leading pediatric neuro-oncologists and look forward to the completion of this trial. This study is an important element of our forward development strategy for XERECEPT®, which we expect to be in registrational trials in the second half of 2010."

XERECEPT® is an investigational new drug that may present an alternative to dexamethasone for patients with primary and metastatic brain tumors.  XERECEPT® has shown in Phase II and Phase III studies that it may provide a safe and effective alternative to corticosteroid treatment for tumor-related brain edema and that it may also have direct anti-tumor activity.  Dexamethasone is currently the standard treatment for peritumoral brain edema, but is associated with debilitating side effects including diabetes mellitus, hypertension, muscle weakness, bone loss, impaired wound healing and opportunistic infections.  

About Celtic Pharmaceutical Holdings L.P.

Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) is a global private equity investment firm focused on the biotechnology and pharmaceutical industries.  Celtic Pharma was founded by Stephen Evans-Freke and John Mayo, CBE and is based in Bermuda, with offices in New York and London.  Celtic Pharma has acquired and invested in late stage pharmaceutical programs and manages these programs through their development for ultimate sale to established pharmaceutical companies.  Celtic Pharma is fully invested at this time.  Celtic Pharma's aim has been to bridge the gap between the established pharmaceutical companies' new product pipeline crisis and the biotech industry's capital drought.  For further information, please visit Celtic Pharma's website at www.celticpharma.com.

Trial Sites

This trial will accrue patients at Children's Memorial Hospital, a member of the Lurie Comprehensive Cancer Center at Northwestern University (Stewart Goldman MD – Principal Investigator) and the Dana Farber Cancer Institute, Harvard University (Mark Kieran MD PhD – Principal Investigator).  These hospitals have two of the largest pediatric brain tumor programs in the United States and also have with vast experience in pediatric Phase I trials.

Forward-Looking Statements

Certain statements in this press release that are not historical facts, including statements that are preceded by, or followed by, or that include words such as "may," "expect," "anticipate," "believe," or "plan," or similar statements, are forward-looking statements that involve risks and uncertainties, including risks relating to the results of the clinical trials for XERECEPT® and the ability of Celtic Pharma or Neurobiological Technologies, Inc. (Pink Sheets: NTII) ("NTI") to obtain regulatory approval for XERECEPT®, as well other risks detailed from time to time in NTI's Securities and Exchange Commission filings.  Copies of these filings are available from NTI upon request. Actual results may differ materially from those projected.  These forward-looking statements represent our judgment as of the date of the release.  We disclaim, however, any intent to update these forward-looking statements.


'/>"/>
SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
2. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
3. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
4. Celator(R) Pharmaceuticals Presents New Data on Two Nano-Scale Delivery Platforms at the American Association for Cancer Research
5. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
6. PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
7. Who Is The Next-Generation Pharmacist(TM)?
8. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
9. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
10. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
11. NCPA Commends Pharmacy Provisions in House-Passed Health Care Reform Bill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):